Story

Vogenx Prices IPO at $13 Per Share, Raising $81.3 Million

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Vogenx Prices IPO at $13 Per Share, Raising $81.3 Million
Text size
Background

Vogenx, Inc. (VOGX), a clinical-stage biopharmaceutical firm, announced it has priced its initial public offering of 6,250,000 shares of common stock at $13.00 per share. The pricing represents the high end of the company's previously stated offering range, indicating solid investor demand.

Offering Details

The IPO is expected to generate gross proceeds of approximately $81.3 million for Vogenx, before the deduction of underwriting discounts, commissions, and other offering-related expenses. The company stated that JonesTrading Institutional Services LLC acted as the sole book-running manager for the offering.

Additionally, Vogenx has granted the underwriters a 45-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less standard discounts and commissions. The offering's registration statement was declared effective by the U.S. Securities and Exchange Commission on August 11, 2026.

Sample IUX Markets – In-articleAd

Market Debut and Company Focus

Shares of Vogenx are scheduled to begin trading on the Nasdaq Capital Market on August 12, 2026, under the ticker symbol VOGX. The offering is anticipated to close on August 13, 2026, subject to customary closing conditions.

Vogenx focuses on developing therapeutics for diseases linked to dysfunctions in human metabolism. Its lead product candidate is mizagliflozin, an orally administered small molecule being developed for conditions including post-bariatric hypoglycemia and gastroparesis. The company licensed the worldwide rights to mizagliflozin, excluding Japan, Korea, and Taiwan, from Kissei Pharmaceutical in 2021.

Read next

More on Stocks
Back to latest news

LATEST